Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Melinta Therapeutics Inc (MLNT)

Melinta Therapeutics Inc (MLNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,050
  • Shares Outstanding, K 13,751
  • Annual Sales, $ 96,430 K
  • Annual Income, $ -157,190 K
  • 60-Month Beta 4.16
  • Price/Sales 0.07
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.47
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.93
  • Growth Rate Est. (year over year) +51,861.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3100 +41.94%
on 01/13/20
1.6900 -73.96%
on 12/16/19
-1.1200 (-71.79%)
since 12/13/19
3-Month
0.3100 +41.94%
on 01/13/20
5.6200 -92.17%
on 10/23/19
-3.3700 (-88.45%)
since 10/11/19
52-Week
0.3100 +41.94%
on 01/13/20
10.1000 -95.64%
on 02/07/19
-4.8600 (-91.70%)
since 01/11/19

Most Recent Stories

More News
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company

Melinta Therapeutics, Inc. (the "Company" or "Melinta"), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, confirmed...

MLNT : 0.4400 (-12.00%)
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures

Bids due on March 2, 2020 by 4:00 p.m. Eastern Time

MLNT : 0.4400 (-12.00%)
Delisting of Securities of Yangtze River Port and Logistics Limited, USA Technologies, Inc., Sienna Biopharmaceuticals, Inc., Melinta Therapeutics, Inc., and Jason Industries, Inc., from The Nasdaq Stock Market

The Nasdaq Stock Market announced today that it will delist the common stock of Yangtze River Port and Logistics Limited. Yangtze River Port and Logistics Limited's stock was suspended on August 20, 2019...

MLNT : 0.4400 (-12.00%)
NDAQ : 95.22 (+1.34%)
SNNA : 0.14 (+34.46%)
USAT : 4.4000 (-6.38%)
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility

Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the "Company" or "Melinta"), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections,...

MLNT : 0.4400 (-12.00%)
NavaDerm Partners adds Dan Wechsler as Executive Chairman

NavaDerm Partners ("NavaDerm" or the "Company"), a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners ("BelHealth"), a New York-based healthcare private...

MLNT : 0.4400 (-12.00%)
MRK : 76.25 (-0.81%)
PFE : 33.64 (+2.34%)
Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates

Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 10.88% and 2.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

MLNT : 0.4400 (-12.00%)
Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019

Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it...

MLNT : 0.4400 (-12.00%)
Arrevus Secures Support from the North Carolina Biotechnology Center to Advance ARV-1801 for the Treatment of Pulmonary Exacerbations in Cystic Fibrosis Patients and Appoints Robert J. Schotzinger, M.D., Ph.D. to the Board of Directors

Arrevus Inc. (www.arrevus.com), a biotechnology company developing novel therapeutics for patients with unmet medical needs, today announced the receipt of a Small Business Research Loan from the North...

MLNT : 0.4400 (-12.00%)
Company News For Oct 28, 2019

Companies in the news are: AMZN, BOOM, RMD, MLNT

AMZN : 1,906.59 (-0.64%)
RMD : 152.97 (+1.89%)
BOOM : 24.14 (+3.83%)
MLNT : 0.4400 (-12.00%)
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA(R) (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~

MLNT : 0.4400 (-12.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MLNT with:

Key Turning Points

2nd Resistance Point 0.5533
1st Resistance Point 0.4967
Last Price 0.4400
1st Support Level 0.3467
2nd Support Level 0.2533

See More

52-Week High 10.1000
Fibonacci 61.8% 6.3602
Fibonacci 50% 5.2050
Fibonacci 38.2% 4.0498
Last Price 0.4400
52-Week Low 0.3100

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar